Prot #VX14-661-110: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F50

Project: Research project

StatusActive
Effective start/end date10/12/1510/12/19

Funding

  • Quintiles, Inc. (Prot #VX14-661-110)
  • Vertex Pharmaceuticals Incorporated (Prot #VX14-661-110)